| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/18/2006 | US7030119 Method for treating chronic pain using MEK inhibitors |
| 04/18/2006 | US7030118 Pyrrolotriazinone compounds and their use to treat diseases |
| 04/18/2006 | US7030117 Sodium channel blockers |
| 04/18/2006 | US7030116 Compounds and compositions as cathepsin inhibitors |
| 04/18/2006 | US7030115 Anticancer agents; autoimmune diseases; antiinflammatory agents |
| 04/18/2006 | US7030114 Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 04/18/2006 | US7030113 Aminobenzimidazoles as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders |
| 04/18/2006 | US7030112 Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders |
| 04/18/2006 | US7030111 drugs such as 4-chloro-benzoic acid p-tolyl ester, used to control or suppress the onset of mitosis until DNA replication and repair are complete; prophylaxis of proliferative disorders |
| 04/18/2006 | US7030110 Cyclic oxyguanidine pyrazinones as protease inhibitors |
| 04/18/2006 | US7030109 1,2,3,4,5,6-Hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position |
| 04/18/2006 | US7030108 Administering to patient effective amount of neurotransmission modulating composition comprising 5HT antagonist and/or alpha 2 antagonist |
| 04/18/2006 | US7030107 nitrogen compounds such as 5-[3,5-bis(trifluoromethyl)benzyl]-6-oxo-7-phenyl-9-[4-(pyrrolidine-1-yl)piperidine-1-yl]-2,3,4,5-tetrahydro-6H-pyrido[2,3-b][1,5]oxazocine, used as neurokinin inhibitors for prophylaxis of urogenital disorders; side effect reduction |
| 04/18/2006 | US7030106 Ezetimibe formulation with lactose, croscarmellose sodium, povidone, sodium lauryl sulfate, magnesium stearate and microcrystalline cellulose |
| 04/18/2006 | US7030105 Method of synthesis of β-thiolato cobalamin compounds |
| 04/18/2006 | US7030104 Topical oestroprogestational compositions with a systemic effect |
| 04/18/2006 | US7030103 Such as ((benzylsulfonylamino)methyl)-phosphonic acid mono-(4-nitrophenyl)ester sodium salt; for treating bacterial antibiotic resistance |
| 04/18/2006 | US7030102 Highly bioavailable coenzyme Q-10 cyclodextrin complex |
| 04/18/2006 | US7030101 A beta-glucan and specific antibodies, such as antibodies specific to Staphylococcus Type 5 antigen or Type 8 antigen; IGIV (immune globulin intravenous) |
| 04/18/2006 | US7030100 Analgesic inhibitor of isoforms of cyclic guanosine monophosphate (cGMP)-dependent protein kinase I alpha (PKGI alpha); drug screening |
| 04/18/2006 | US7030099 Tumor specific promoters of the midkine gene that allow for selective expression in P53-inactivated cells |
| 04/18/2006 | US7030098 DNA vaccination for treatment of autoimmune disease |
| 04/18/2006 | US7030097 Controlled nucleic acid delivery systems |
| 04/18/2006 | US7030096 transduction of DNA sequences by naked DNA transfer, expression of genes that code for muscle tone controllers; gene therapy for prophylaxis of erectile dysfunction, urogenital and muscular disorders |
| 04/18/2006 | US7030095 Mixture containing spinosyn a and d |
| 04/18/2006 | US7030094 Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and QS-21 |
| 04/18/2006 | US7030093 Antibiotic coating for porous bodies and method for its production as well as its use |
| 04/18/2006 | US7030092 Ultra-high fiber supplement and method of reducing weight cardiovascular risks and ingested toxins. |
| 04/18/2006 | US7030089 Use of substituted acryloyl distamycin derivatives in the treatment of tumors associated with high levels of glutathione |
| 04/18/2006 | US7030087 A water-soluble polypeptide having hydrophobic side chains, for use as bactericides treating infections, detoxification of endotoxin, cell antiproliferative agents, antagonist of tumor necrosis factor |
| 04/18/2006 | US7030085 Thiopeptide compounds |
| 04/18/2006 | US7030081 Muteins of the Ser-Cys-Asn-Thr-Ala-Thr-Cys sequence from the N- terminal 1-7 fragment of the CGRP (calcitonin gene related peptide), activates neuronal nicotinic receptor, therefor useful for therapy of neurological disorders |
| 04/18/2006 | US7029914 DNA encoding SNORF36 receptors |
| 04/18/2006 | US7029898 Comprises chimeric polypeptide with hydrolase and mitogen activated protein kinase activity for diagnosis and treatment of cell proliferation and differentiation disorders |
| 04/18/2006 | US7029849 Kit for use in the diagnosis of hypertension; obtain sample, determine pattern of alleles, detect preferential gene expression, preferential gene expression indicates hypertension |
| 04/18/2006 | US7029712 Treatment for dry eye syndrome |
| 04/18/2006 | US7029710 For inhibiting amyloid formation, deposition, accumulation, or persistence, or amyloid protein-amyloid protein interactions, amyloid-proteoglycan interactions, amyloid-PG/GAG interactions and/or amyloid-glycosaminoglycan interactions |
| 04/18/2006 | US7029708 Herbal supplement for cognitive related impairment due to estrogen loss |
| 04/18/2006 | US7029707 Method of producing a processed kava product having an altered kavalactone distribution and processed kava products produced using the same |
| 04/18/2006 | US7029706 Composition for the treatment of cutaneous mycosis |
| 04/18/2006 | US7029704 hydrogen peroxide, sodium bicarbonate and apple cider vinegar applied to feet to prevent athlete's foot |
| 04/18/2006 | US7029703 Composition for promoting healthy bone structure |
| 04/18/2006 | US7029701 Composition for the treatment and prevention of ischemic events |
| 04/18/2006 | US7029698 Solubility characteristics for encapsulation; capsular dosage forms |
| 04/18/2006 | US7029696 Delivery and activation through liposome incorporation of diaminocyclohexane platinum(II) complexes |
| 04/18/2006 | US7029694 Compositions and methods for transdermal oxybutynin therapy |
| 04/18/2006 | US7029692 content of monoterpene ketone in the nicotine-containing layer is 0.1 to 5.0%-wt of the weight; masks the unpleasant smell of nicotine |
| 04/18/2006 | US7029691 Conjugated linoleic acid compositions |
| 04/18/2006 | US7029688 Methods and compositions to prevent formation of adhesions in biological tissues |
| 04/18/2006 | US7029681 Multiple and multivalent DNA vaccines in ovo |
| 04/18/2006 | US7029672 Use of quinone Q10 for the treatment of ocular diseases |
| 04/18/2006 | US7029671 Method for activating human antigen-presenting cells, activated human antigen-presenting cells, and use thereof |
| 04/18/2006 | US7029665 Human suppressor tRNA oligonucleotides and methods for use for same |
| 04/18/2006 | US7029663 substantially anhydrous, using hydrocarbon gel and/or petrolatum as a base; increased storage stability |
| 04/18/2006 | US7029660 Cosmetic or dermatological light-protective formulation comprising a benzotriazole and a benzoxazole derivative |
| 04/18/2006 | US7029659 aqueous solvent, organic cosolvent, and occlusive agent, especially petrolatum, to form an occlusive layer on the skin for the topical administration of pharmaceuticals |
| 04/18/2006 | US7029658 Delivery of antidepressants through an inhalation route |
| 04/18/2006 | US7029657 Nasal spray steroid formulation and method |
| 04/18/2006 | US7029656 Methods and formulations for the efficient delivery of water-insoluble drugs by nebulizer |
| 04/18/2006 | US7029654 anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage |
| 04/18/2006 | US7029653 Method of the administration of drugs having binding affinity with plasma protein and preparation to be used in the method |
| 04/18/2006 | US7029473 Deflectable spacer for use as an interspinous process implant and method |
| 04/18/2006 | US7028921 Catalyst solution dispenser for a hand-held liquid spraying apparatus |
| 04/18/2006 | CA2409059C Stabilized aqueous suspensions for parenteral use |
| 04/18/2006 | CA2346335C Sertraline oral concentrate |
| 04/18/2006 | CA2302819C Use of a substance agonist of a receptor associated with a chlorine or potassium canal for treating sensitive skins |
| 04/18/2006 | CA2273374C Trioxane dimer compounds having antiproliferative and antitumor activities |
| 04/18/2006 | CA2268825C Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
| 04/18/2006 | CA2247513C Camptothecin derivatives and the use thereof as antitumor agents |
| 04/18/2006 | CA2238710C New amino alcohol derivatives, processes for their production and pharmaceutical agents containing these compounds |
| 04/18/2006 | CA2205230C N-hydroxypiperidines as superoxide radicals scavengers |
| 04/18/2006 | CA2156079C Novel derivatives of 3-hydroxy anthranilic acid, methods and intermediates for their preparation, novel pharmaceutial compositions and the use thereof |
| 04/18/2006 | CA2155666C Novel derivatives of 3-hydroxy anthranilic acid, methods and intermediates for their preparation, novel pharmaceutical compositions and the use thereof |
| 04/18/2006 | CA2148943C Oxidation of glycoside substituted taxanes to taxol or taxol precursors and new taxane compounds formed as intermediates |
| 04/14/2006 | WO2005032544A1 Treatment of mitochondrial diseases |
| 04/14/2006 | CA2580584A1 Use of alpha-tocotrienol for treatment of mitochondrial diseases |
| 04/13/2006 | WO2006039709A1 Methods using glycosaminoglycans for the treatment of kidney disease |
| 04/13/2006 | WO2006039704A2 Pharmaceutical composition and method for treating a joint capsule arthropathy |
| 04/13/2006 | WO2006039691A2 Morphine and morphine precursors |
| 04/13/2006 | WO2006039667A2 Water-based delivery systems |
| 04/13/2006 | WO2006039663A2 Methods for the administration of iloperidone |
| 04/13/2006 | WO2006039639A1 Crystalline forms and process for preparing spiro-hydantoin compounds |
| 04/13/2006 | WO2006039569A1 Combination therapy of hedgehog inhibitors, radiation and chemotherapeutic agents |
| 04/13/2006 | WO2006039551A2 Local administration of retinoids to treat deficiencies in dark adaptation |
| 04/13/2006 | WO2006039527A1 Macrocyclic sh2 domain binding inhibitors |
| 04/13/2006 | WO2006039441A2 Amorphous atorvastatin calcium |
| 04/13/2006 | WO2006039414A2 Treatment method |
| 04/13/2006 | WO2006039356A2 Substituted n-aryl-9-oxo-9h-fluorene-1-carboxamides and analogs as activators of caspases and inducers of apoptosis |
| 04/13/2006 | WO2006039336A2 Conveniently implantable sustained release drug compositions |
| 04/13/2006 | WO2006039334A1 Combinations of substituted azetidonones and cb1 antagonists |
| 04/13/2006 | WO2006039327A2 Methods of treatment or prophylaxis of amyloidogenic diseases of the eye or optic nerve |
| 04/13/2006 | WO2006039325A2 Aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| 04/13/2006 | WO2006039285A2 Compositions and methods for inducing adipose tissue cell death |
| 04/13/2006 | WO2006039281A2 Skin cancer prevention method and product |
| 04/13/2006 | WO2006039263A2 NOVEL BICYCLIC 9a-AZALIDE DERIVATIVES |
| 04/13/2006 | WO2006039252A2 Compositions and methods for treating ophthalmic diseases |
| 04/13/2006 | WO2006039250A2 Chemokine-binding heterocyclic compound salts, and methods of use thereof |
| 04/13/2006 | WO2006039243A1 Novel benzimidazole derivatives useful as selective androgen receptor modulators (sarms) |
| 04/13/2006 | WO2006039237A1 Pharmaceutical dosage forms of stable amorphous rapamycin like compounds |
| 04/13/2006 | WO2006039231A2 Topical formulations for the treatment of depression with s adenosyl methionine |